_id
690db00cccc777a4e85d0b4c
Ticker
APTOF
Name
DMD Digital Health Connections Group Inc
Exchange
NASDAQ
Address
66 Wellington Street West, Toronto, ON, Canada, M5K 1E6
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.aptose.com
Description
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Last Close
1.6
Volume
3366
Current Price
1.6001
Change
-0.0199
Last Updated
2026-01-20T15:33:38.736Z
Image
data:image/webp;base64,UklGRsYBAABXRUJQVlA4ILoBAAAQCwCdASpAAEAAPtFep0+oJKMiKBgKqQAaCWMA0DiQ//qklY/76CMA7LgyZVZNB8ibNv4DKAjZB2isxnEuwtmSSnWiXJfbd7zwJUTXIM5tloGGKE5LnNJtxNdZTn7w2z7gAP7ylFp/bb34eawP/90fkz7rjB4Vged7vuG9AIZDESyxWLgQqo2hQKsXgf4fCfyo6fEHa0+HI3kNnfxy2UjjpdOW2aGXMIJenov2xDHBuN59EtXlutLzdu+1YgpzufrIUm2VXxspZDoWMOIQEU47ReNTQJWJZJq0SzuJozbcKx8dV38dOYwPGUFS3HKfGYgLxV6f9lJ/NS9trZHsBhn0DqZ5E6Z+RFtwjqWznqPdv52QhEXYIzK+QLZaCy/ymQOrkk0x73lv0p5kroAl4bRwBOa0ZXSQSfFnyDhriQIjHNMwe3f1DQbIcWU6R6ef6nISHIgRzh9rfxKgaGnk+g9uB5hIrVtNRR2qiTpzmtnvhCu6lp3IAU4QB0BE2OAAUXM4LvDu1ru5VDOIFW3RvGGSHDmzBPs18JbuWlzjaxfKpaYZSqRVm+T9GAAvx1X+nYiGsNIP8GAAAAAA
Ipo Date
2014-10-23T00:00:00.000Z
Market Cap
4134935
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
5
Target Price
12.5
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
4913000
Operating Income
-4913000
Interest Expense
-
Pretax Income
-5123000
Net Income
-5123000
Eps
-2.0071077393337875
Dividends Per Share
-
Shares Outstanding
2552429
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
2000
Cash
613000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
3777000
Property Plant Equipment
285000
Total Assets
6341000
Payables
1456000
Short Term Debt
-
Long Term Debt
18712000
Total Liabilities
25791000
Equity
-19450000
Bs_currency_symbol
USD
Depreciation
111000
Change In Working Capital
-2555000
Cash From Operations
-7411000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
7750000
Net Change In Cash
339000
Cf_currency_symbol
USD
PE
2.3478
PB
-0.20998157547043703
ROE
26.339331619537276
ROA
-80.79167323765968
FCF
-7411000
Fcf Percent
-
Piotroski FScore
0
Health Score
38
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
4
Net Net Investing Score
0.5
Quality Investing Score
3
Value Investing Score
7
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
4913000
Quarters > 0 > income Statement > operating Income
-4913000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-5123000
Quarters > 0 > income Statement > net Income
-5123000
Quarters > 0 > income Statement > eps
-2.0071077393337875
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
2552429
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
613000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
3777000
Quarters > 0 > balance Sheet > property Plant Equipment
285000
Quarters > 0 > balance Sheet > total Assets
6341000
Quarters > 0 > balance Sheet > payables
1456000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
18712000
Quarters > 0 > balance Sheet > total Liabilities
25791000
Quarters > 0 > balance Sheet > equity
-19450000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-5123000
Quarters > 0 > cash Flow > depreciation
111000
Quarters > 0 > cash Flow > change In Working Capital
-2555000
Quarters > 0 > cash Flow > cash From Operations
-7411000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
7750000
Quarters > 0 > cash Flow > net Change In Cash
339000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-2.0071077393337875
Quarters > 0 > ratios > PB
-0.20998157547043703
Quarters > 0 > ratios > ROE
26.339331619537276
Quarters > 0 > ratios > ROA
-80.79167323765968
Quarters > 0 > ratios > FCF
-7411000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
6921000
Quarters > 1 > income Statement > operating Income
-6921000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-7043000
Quarters > 1 > income Statement > net Income
-7043000
Quarters > 1 > income Statement > eps
-2.759332384955664
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
2552429
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-12000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
553000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
3271000
Quarters > 1 > balance Sheet > property Plant Equipment
396000
Quarters > 1 > balance Sheet > total Assets
5591000
Quarters > 1 > balance Sheet > payables
2879000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
10962000
Quarters > 1 > balance Sheet > total Liabilities
19962000
Quarters > 1 > balance Sheet > equity
-14371000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-7043000
Quarters > 1 > cash Flow > depreciation
102000
Quarters > 1 > cash Flow > change In Working Capital
908000
Quarters > 1 > cash Flow > cash From Operations
-5943000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2500000
Quarters > 1 > cash Flow > net Change In Cash
-3445000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-2.759332384955664
Quarters > 1 > ratios > PB
-0.28419328111474496
Quarters > 1 > ratios > ROE
49.0084197341869
Quarters > 1 > ratios > ROA
-125.97030942586301
Quarters > 1 > ratios > FCF
-5943000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
5461000
Quarters > 2 > income Statement > operating Income
-5461000
Quarters > 2 > income Statement > interest Expense
84000
Quarters > 2 > income Statement > pretax Income
-5543000
Quarters > 2 > income Statement > net Income
-5543000
Quarters > 2 > income Statement > eps
-2.1716568805635728
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
2552429
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
4700000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
6969000
Quarters > 2 > balance Sheet > property Plant Equipment
498000
Quarters > 2 > balance Sheet > total Assets
7467000
Quarters > 2 > balance Sheet > payables
2390000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
8462000
Quarters > 2 > balance Sheet > total Liabilities
14860000
Quarters > 2 > balance Sheet > equity
-7393000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-5543000
Quarters > 2 > cash Flow > depreciation
99000
Quarters > 2 > cash Flow > change In Working Capital
2280000
Quarters > 2 > cash Flow > cash From Operations
-2795000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
829000
Quarters > 2 > cash Flow > net Change In Cash
-1964000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-2.1716568805635728
Quarters > 2 > ratios > PB
-0.5524336051535237
Quarters > 2 > ratios > ROE
74.97632895982687
Quarters > 2 > ratios > ROA
-74.23329315655552
Quarters > 2 > ratios > FCF
-2795000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
2187000
Quarters > 3 > income Statement > operating Income
-2187000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1585000
Quarters > 3 > income Statement > net Income
-1585000
Quarters > 3 > income Statement > eps
-0.7901189764644244
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
2006027
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
678000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
6152000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
9530000
Quarters > 3 > balance Sheet > property Plant Equipment
597000
Quarters > 3 > balance Sheet > total Assets
10127000
Quarters > 3 > balance Sheet > payables
1258000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
10018000
Quarters > 3 > balance Sheet > total Liabilities
14670000
Quarters > 3 > balance Sheet > equity
-4543000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-1585000
Quarters > 3 > cash Flow > depreciation
97000
Quarters > 3 > cash Flow > change In Working Capital
-5515000
Quarters > 3 > cash Flow > cash From Operations
-8060000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
6805000
Quarters > 3 > cash Flow > net Change In Cash
-1255000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.7901189764644244
Quarters > 3 > ratios > PB
-0.7065471720669162
Quarters > 3 > ratios > ROE
34.88883997358573
Quarters > 3 > ratios > ROA
-15.651229386787795
Quarters > 3 > ratios > FCF
-8060000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
38
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
26257000
Annuals > 0 > income Statement > operating Income
-26257000
Annuals > 0 > income Statement > interest Expense
207000
Annuals > 0 > income Statement > pretax Income
-25430000
Annuals > 0 > income Statement > net Income
-25430000
Annuals > 0 > income Statement > eps
-12.676798467817234
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
2006027
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
677000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
6152000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
9530000
Annuals > 0 > balance Sheet > property Plant Equipment
597000
Annuals > 0 > balance Sheet > total Assets
10127000
Annuals > 0 > balance Sheet > payables
1258000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
10018000
Annuals > 0 > balance Sheet > total Liabilities
14670000
Annuals > 0 > balance Sheet > equity
-4543000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-25430000
Annuals > 0 > cash Flow > depreciation
404000
Annuals > 0 > cash Flow > change In Working Capital
-11025000
Annuals > 0 > cash Flow > cash From Operations
-35977000
Annuals > 0 > cash Flow > capital Expenditures
5000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
33414000
Annuals > 0 > cash Flow > net Change In Cash
-2545000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-12.676798467817234
Annuals > 0 > ratios > PB
-0.7065471720669162
Annuals > 0 > ratios > ROE
559.7622716266784
Annuals > 0 > ratios > ROA
-251.11089167571836
Annuals > 0 > ratios > FCF
-35982000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
52356000
Annuals > 1 > income Statement > operating Income
-52356000
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-51207000
Annuals > 1 > income Statement > net Income
-51207000
Annuals > 1 > income Statement > eps
-193.42008347655292
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
264745
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-2000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
9252000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
11894000
Annuals > 1 > balance Sheet > property Plant Equipment
1095000
Annuals > 1 > balance Sheet > total Assets
12989000
Annuals > 1 > balance Sheet > payables
3492000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
15890000
Annuals > 1 > balance Sheet > equity
-2901000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-51207000
Annuals > 1 > cash Flow > depreciation
466000
Annuals > 1 > cash Flow > change In Working Capital
2810000
Annuals > 1 > cash Flow > cash From Operations
-44590000
Annuals > 1 > cash Flow > capital Expenditures
29000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
6910000
Annuals > 1 > cash Flow > net Change In Cash
-27718000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-193.42008347655292
Annuals > 1 > ratios > PB
-0.14602498259220958
Annuals > 1 > ratios > ROE
1765.149948293692
Annuals > 1 > ratios > ROA
-394.23358226191397
Annuals > 1 > ratios > FCF
-44619000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
42602000
Annuals > 2 > income Statement > operating Income
-42602000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-41823000
Annuals > 2 > income Statement > net Income
-41823000
Annuals > 2 > income Statement > eps
-203.75621163402514
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
205260
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-9000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
36970000
Annuals > 2 > balance Sheet > short Term Investments
9989000
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
49519000
Annuals > 2 > balance Sheet > property Plant Equipment
1508000
Annuals > 2 > balance Sheet > total Assets
51027000
Annuals > 2 > balance Sheet > payables
3342000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
13286000
Annuals > 2 > balance Sheet > equity
37741000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-41823000
Annuals > 2 > cash Flow > depreciation
528000
Annuals > 2 > cash Flow > change In Working Capital
4317000
Annuals > 2 > cash Flow > cash From Operations
-32322000
Annuals > 2 > cash Flow > capital Expenditures
24000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
116000
Annuals > 2 > cash Flow > net Change In Cash
-2144000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-203.75621163402514
Annuals > 2 > ratios > PB
0.008702380064121249
Annuals > 2 > ratios > ROE
-110.81582364007312
Annuals > 2 > ratios > ROA
-81.96249044623436
Annuals > 2 > ratios > FCF
-32346000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
65447000
Annuals > 3 > income Statement > operating Income
-65447000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-65354000
Annuals > 3 > income Statement > net Income
-65354000
Annuals > 3 > income Statement > eps
-318.9213456827476
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
204922
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-1000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
39114000
Annuals > 3 > balance Sheet > short Term Investments
40014000
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
81737000
Annuals > 3 > balance Sheet > property Plant Equipment
788000
Annuals > 3 > balance Sheet > total Assets
82525000
Annuals > 3 > balance Sheet > payables
1699000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
8289000
Annuals > 3 > balance Sheet > equity
74236000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-65354000
Annuals > 3 > cash Flow > depreciation
622000
Annuals > 3 > cash Flow > change In Working Capital
1516000
Annuals > 3 > cash Flow > cash From Operations
-43304000
Annuals > 3 > cash Flow > capital Expenditures
212000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
226000
Annuals > 3 > cash Flow > net Change In Cash
-78279000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-318.9213456827476
Annuals > 3 > ratios > PB
0.004416936421682203
Annuals > 3 > ratios > ROE
-88.0354544964707
Annuals > 3 > ratios > ROA
-79.19297182671917
Annuals > 3 > ratios > FCF
-43516000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
2.3478
Valuation > metrics > PB
-0.20998157547043703
Valuation > final Score
70
Valuation > verdict
76.5% Undervalued
Profitability > metrics > ROE
26.339331619537276
Profitability > metrics > ROA
-135.63674874238814
Profitability > final Score
55
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-2456.5
Risk > final Score
-9796
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.5940934065934065
Liquidity > metrics > Quick Ratio
2.5940934065934065
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
55
Prev Profitabilities > 2
55
Prev Risks > 0
-2277
Prev Risks > 1
-230
Prev Risks > 2
17
Prev Liquidities > 0
78
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:24:07.628Z
Earnings History > 0 > period
2025-06-30
Earnings History > 0 > report Date
2025-06-30
Earnings History > 0 > date
2025-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-2.76
Earnings History > 0 > eps Estimate
-2.74
Earnings History > 0 > eps Difference
-0.02
Earnings History > 0 > surprise Percent
-0.7299
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-03-31
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-2.61
Earnings History > 1 > eps Estimate
-2.67
Earnings History > 1 > eps Difference
0.06
Earnings History > 1 > surprise Percent
2.2472
Earnings History > 2 > period
2024-12-31
Earnings History > 2 > report Date
2024-12-31
Earnings History > 2 > date
2024-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-34.9
Earnings History > 2 > eps Estimate
-6.775
Earnings History > 2 > eps Difference
-28.125
Earnings History > 2 > surprise Percent
-415.1292
Earnings History > 3 > period
2024-09-30
Earnings History > 3 > report Date
2024-09-30
Earnings History > 3 > date
2024-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-11.1
Earnings History > 3 > eps Estimate
-19.2
Earnings History > 3 > eps Difference
8.1
Earnings History > 3 > surprise Percent
42.1875
Earnings History > 4 > period
2024-06-30
Earnings History > 4 > report Date
2024-06-30
Earnings History > 4 > date
2024-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-12.9
Earnings History > 4 > eps Estimate
-17.4
Earnings History > 4 > eps Difference
4.5
Earnings History > 4 > surprise Percent
25.8621
Earnings History > 5 > period
2024-03-31
Earnings History > 5 > report Date
2024-03-31
Earnings History > 5 > date
2024-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-21.9
Earnings History > 5 > eps Estimate
-24.6
Earnings History > 5 > eps Difference
2.7
Earnings History > 5 > surprise Percent
10.9756
Earnings History > 6 > period
2017-06-30
Earnings History > 6 > report Date
2017-06-30
Earnings History > 6 > date
2017-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-0.12
Earnings History > 6 > eps Estimate
-0.24
Earnings History > 6 > eps Difference
0.12
Earnings History > 6 > surprise Percent
50
Earnings History > 7 > period
2016-12-31
Earnings History > 7 > report Date
2016-12-31
Earnings History > 7 > date
2016-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
-0.23
Earnings History > 7 > eps Estimate
-0.25
Earnings History > 7 > eps Difference
0.02
Earnings History > 7 > surprise Percent
8
Earnings History > 8 > period
2016-09-30
Earnings History > 8 > report Date
2016-09-30
Earnings History > 8 > date
2016-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
-0.24
Earnings History > 8 > eps Estimate
-0.33
Earnings History > 8 > eps Difference
0.09
Earnings History > 8 > surprise Percent
27.2727
Earnings History > 9 > period
2016-06-30
Earnings History > 9 > report Date
2016-06-30
Earnings History > 9 > date
2016-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
-0.36
Earnings History > 9 > eps Estimate
-0.29
Earnings History > 9 > eps Difference
-0.07
Earnings History > 9 > surprise Percent
-24.1379
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical GlobeNewswire
Read more →Showing 2 of 5
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$12.5
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of DMD Digital Health Connections Group Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-06-30
EPS Actual
-2.76
EPS Estimate
-2.74
EPS Difference
-0.02
Surprise Percent
-0.7299%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.